Medical technology company Xcision Medical Systems LLC said on Monday that Azienda Universitaria Integrata di Udine (ASUIUD) in Italy has announced its plans to acquire the GammaPod Stereotactic Radiotherapy System for the treatment of breast cancer.

The GammaPod Stereotactic Radiotherapy System is a new treatment system that offers shorter courses of highly conformal radiotherapy for women with breast cancer. It is a new tool designed to deliver noninvasive stereotactic partial breast irradiation treatments to breast cancer patients. The delivery of higher doses in one or several large fractions differentiates stereotactic radiotherapy from conventional techniques. The GammaPod uses a first-of-its kind breast cup system that immobilizes the affected breast to minimize motion and provides stereotactic localization for treatment planning.

Additionally, the GammaPod has received 510(k) clearance from the US FDA. In Europe, GammaPod is for investigational use only and cannot be marketed or put into service until it has been made to comply with the Medical Device Directive (93/42/EEC).

In Italy, Tema Sinergie SpA is reportedly the exclusive distributor of the GammaPod system.

Following the acquisition, ASUIUD will join the GammaPod Research Consortium, which was founded by the University of Maryland School of Medicine in Baltimore, to investigate postoperative and preoperative applications for GammaPod.